58531-92-3 Usage
Uses
Used in Pharmaceutical Industry:
(amino[4-(dimethylamino)phenyl]methylidenecarbonohydrazonoyl)selanyl is used as a potential pharmaceutical compound for its unique structure and potential medicinal properties. (amino[4-(dimethylamino)phenyl]methylidenecarbonohydrazonoyl)selanyl's specific application within the pharmaceutical industry would require further research and analysis to determine its efficacy and safety.
Used in Chemical Industry:
(amino[4-(dimethylamino)phenyl]methylidenecarbonohydrazonoyl)selanyl may also be used as a complex organic compound in the chemical industry for various purposes, such as the development of new materials or the synthesis of other compounds. Its potential applications in this industry would also require further research and analysis to fully understand its capabilities and limitations.
Check Digit Verification of cas no
The CAS Registry Mumber 58531-92-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,5,3 and 1 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 58531-92:
(7*5)+(6*8)+(5*5)+(4*3)+(3*1)+(2*9)+(1*2)=143
143 % 10 = 3
So 58531-92-3 is a valid CAS Registry Number.
58531-92-3Relevant academic research and scientific papers
New approach towards the synthesis of selenosemicarbazones, useful compounds for Chagas' disease
Pizzo, Chiara,Faral-Tello, Paula,Yaluff, Gloria,Serna, Elva,Torres, Susana,Vera, Ninfa,Saiz, Cecilia,Robello, Carlos,Mahler, Graciela
, p. 107 - 113 (2016/01/15)
Herein, we describe a new approach towards the synthesis of selenosemicarbazones. The reaction involves an O-Se exchange of semicarbazones using Ishihara reagent. Eleven selenosemicarbazones were prepared using this methodology, with low to moderate yields. Among the prepared compounds the m-bromo phenyl methyl derivative 1b was selected to be evaluated in vivo, in a murine model of acute Chagas' disease. Compound 1b 10 mg/kg bw/day reduced 50% of parasitaemia profile compared with the control group, but was less effective than Benznidazole (50 mg/kg bw/day reduced 90%) and toxic. These studies are important to guide future Chagas drug design.
